PUBLICATION BY MATTHIAS MAGOOLA, CHEMIST

Abstract: Therapeutic proteins treat many acute and chronic diseases that were until recently consid- ered untreatable. However, their high development cost keeps them out of reach of most patients around the world.

One plausible solution to lower-cost manufacturing is to adopt newer tech- nologies like using Escherichia coli to express larger molecules, including full-length antibodies, generally relegated to Chinese Hamster Ovary (CHO) cells, adopt continuous manufacturing, and convert the manufacturing to cell-free synthesis.

The advantages of using E. coli include a shorter production cycle, little risk of viral contamination, cell host stability, and a highly reproducible post-translational modification.